Resistance to tyrosine kinase inhibitors of EGFR in NSCLC is driven by constitutive activation of S6K1, with p-S6K1 levels higher in the gefitinib-resistant lung cancer cells and PDX tumors compared to the gefitinib-sensitive lung cancer and parental PDX tumors, respectively. This evidence concerns the gene EGFR and lung carcinoma.